The company doesn't seem like it will generate pops in key fundamentals anytime soon.

The firm is projecting a gradual recovery of the academic market in the face of ongoing funding uncertainties and a government shutdown.

The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...

Oct 14 (Reuters) - U.S. biotech firm Nabla Bio said on Tuesday it has signed a second major research partnership with Japanese drugmaker Takeda Pharmaceutical (4502.T), opens new tab, deepening their ...

-Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven ...

I’ll start this feature with a gesture of gratitude that the former Pandora’s Pizza spot on Coast Highway and Leucadia Boulevard is back to being what it was meant to be, a pizza joint at heart with a ...